ArticleNephron2024
Disease Burden and Epidemiological Trends of Chronic Kidney Disease at the Global, Regional, National Levels from 1990 to 2019.
Article in Nephron, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 5 syntheses or guidelines pooled it, 97 citations in OpenAlex.
- Frailty in maintenance hemodialysis: a systematic review and meta-analysis of prevalence and risk factors.International urology and nephrology · 2026Pooled it
- The association between anti-inflammatory therapies and renal outcomes in patients with established cardiovascular disease or high cardiovascular risks: a meta-analysis of randomised controlled trials.Inflammopharmacology · 2025Pooled it
- Pooled it
- Artificial intelligence in predicting chronic kidney disease prognosis. A systematic review and meta-analysis.Renal failure · 2024Pooled it
- The Etiology of Advanced Chronic Kidney Disease in Southeast Asia: A Meta-analysis.Journal of epidemiology and global health · 2024Pooled it
- LactuloseWorld journal of nephrology · 2026Article
- Urinary collagen type I degradation products as common fibrosis biomarkers in chronic diseases.Molecular medicine (Cambridge, Mass.) · 2026Article
- Prognostic value of RDW and its derivatives in ICU patients with hypertensive chronic kidney disease.BMC cardiovascular disorders · 2026Article
- Empagliflozin, Linagliptin, and Metformin Differentially Affect Renal PI3K/Akt and MAPK/ERK Signaling Pathways inInternational journal of molecular sciences · 2026Article
- Low-dose exposure to organophosphate pesticides and chronic kidney disease: insights from urinary dialkyl phosphate biomarkers.Clinical and experimental nephrology · 2026Article
- Deficit accumulation frailty and risk of incident chronic kidney disease: a prospective analysis of the UK biobank and CHARLS cohorts.International urology and nephrology · 2026Article
- HFpEF Diagnosis: A Challenge in CKD with Current Algorithms.Life (Basel, Switzerland) · 2026Article
- Trends in 10th Revision of the International Classification of Diseases-Coded CKD Incidence Among Chinese Adults.Kidney international reports · 2026Article
- The Global Burden of Chronic Kidney Disease Attributable to Hypertension in Young Adults From 1990 to 2021 and Projections to 2050.Balkan medical journal · 2026Observational
- A Comprehensive Analysis of the Impact of Nutrient Intakes on the Stages and Mortality of Cardiovascular-Kidney-Metabolic Syndrome.Food science & nutrition · 2026Article
- GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease.Nature reviews. Nephrology · 2026Review
- Expanding Kidney Care: How Nonphysician Health Workers Can Address the Global CKD Crisis.Kidney international reports · 2026Review
- CKD in Migrants: From Epidemiology to Challenges.Kidney international reports · 2026Review
- Adherence to the EAT-Lancet diet and risk of chronic kidney disease among middle-aged and older adults: insights from two nationwide cohort studies.Nutrition journal · 2026Article
- Five-Year Outcomes of Chronic Kidney Disease in a Longitudinal Population-Based Cohort in Western Australia.Nephrology (Carlton, Vic.) · 2026Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) is a serious public health issue worldwide, but the disease burden of CKD caused by different etiologies and changing trends has not been fully examined.
methodsWe collected data from Global Burden of Disease Study 2019 (GBD 2019), including incident cases, age-standardized incidence rate (ASIR), disability-adjusted life years (DALYs), and age-standardized DALY rate between 1990 and 2019 by region, etiology, age, and sex, and calculated the estimated annual percentage change (EAPC) of the rate to evaluate the epidemiological trends.
resultsGlobally, incident cases of CKD increased from 7.80 million in 1990 to 18.99 million in 2019, and DALYs increased from 21.50 million to 41.54 million. ASIR increased with an EAPC of 0.69 (95% uncertainty interval [UI] 0.49-0.89) and reached 233.65 per 100,000 in 2019, while the age-standardized DALY rate increased with an EAPC of 0.30 (95% UI 0.17-0.43) and reached 514.86 per 100,000. North Africa and the Middle East, central Latin America, and North America had the highest ASIR in 2019. Central Latin America had the highest age-standardized DALY rate, meanwhile. Almost all countries experienced an increase in ASIR, and over 50% of countries had an increasing trend in age-standardized DALY rate from 1990 to 2019. CKD due to diabetes mellitus type 2 and hypertension accounted for the largest disease burden with 85% incident cases and 66% DALYs in 2019 of known causes, with the highest growth in age-standardized DALY rate and a similar geographic pattern to that of total CKD. Besides, the highest incidence rate of total and four specific CKDs were identified in people aged 70 plus years, who also had the highest DALY rate with a stable trend after 2010. Females had a higher ASIR, while males had a higher age-standardized DALY rate, the gap of which was most distinctive in CKD due to hypertension.
conclusionThe disease burden of CKD remains substantial and continues to grow globally. From 1990 to 2019, global incident cases of CKD have more than doubled and DALYs have almost doubled, and surpassed 40 million years. CKD due to diabetes mellitus type 2 and hypertension contributed nearly 2/3 of DALYs in 2019 of known causes, and had witnessed the highest growth in age-standardized DALY rate. Etiology-specific prevention strategies should be placed as a high priority on the goal of precise control of CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.